Coupe N, Schadendorf D, Danson S, et al. PACMEL: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in Advanced BRAF wild type melanoma. SMR 2017, abstract SMR05-2.
CD44 en MET, partners in carcinogenese van CRC
okt 2021 | Maag-darm-leveroncologie